Niagen Bioscience, Inc. (NAGE) Q2 2026 Earnings Call Transcript
Niagen Bioscience (NAGE) came out with quarterly earnings of $0.01 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.04 per share a year ago.
Niagen Bioscience, Inc. (NAGE) Discusses Strategic Expansion Into Pharmaceutical Development and NB4168 Drug Program Transcript
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
Curtis Ellergodt Rothschild Investment LLC | 725 | $3,344.91 | $1,834.25 | -$1,510.66 | -45.16% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 800 | $2,640 | $2,024 | -$616 | -23.33% |
| BG Bart Gancher Intech Investment Management LLC | 14,463 | $173,337.56 | $37,314.54 | -$136,023.02 | -78.47% |
| KAC Kimberly A. Clarke Stoneridge Investment Partners LLC | 14,477 | $92,051.78 | $37,278.27 | -$54,773.51 | -59.5% |
| CD Charlie Durham Sterling Capital Management LLC | 203 | $1,291.06 | $513.59 | -$777.47 | -60.22% |